Anthony C. Tridico Ph.D.

Partner

Anthony Tridico is the managing partner of Finnegan’s European office in Brussels, Belgium. He practices all aspects of intellectual property law, from strategic patent portfolio management to litigation.

Dr. Tridico’s practice involves diverse technical areas, focusing on pre-litigation analysis and strategic client counseling, due diligence investigations, licensing, patent portfolio management and analysis, prosecution of both U.S. and foreign patent applications, and appeals and oral hearings at the Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office. His litigation practice ranges from protecting the rights of innovative pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigations to defending a client’s right to use diagnostic equipment. He also has vast experience in representing clients in the areas of patent reexamination, including inter partes reexam, reissue, FDA Orange Book listing of patents, and patent term extensions.

Strategic portfolio management and counseling to European clients is an important part of Dr. Tridico’s practice. During his previous tenure in Brussels (2001-2004), he gained significant knowledge about the EPC and the diversity of laws and practice among the European national systems. His knowledge of the European legal system and how it differs from the United States allows Dr. Tridico to effectively counsel both European and U.S. clients with global interests in intellectual property.

Dr. Tridico is a frequent lecturer on intellectual property issues at various international programs and conferences targeted to the U.S. and European business community.

Highlights

• Adjunct professor at Georgetown University Law School.
• Worked as a research scientist at Brookhaven National Laboratory in Upton, N.Y., with experience in laser systems and investigating surface reactions, nucleation, and crystal structures.

Professional Recognition

• Sigma Xi

Professional Activities

• American Intellectual Property Law Association
• American Chemical Society

Select Publications

• Coauthor. "Like Zeus the Supreme Court Punishes Prometheus: But What Does it all Mean for Patentable Subject Matter?" CIPA Journal, April 2012.
• Coauthor. "The ICC Intellectual Property Roadmap for Business and Policymakers," International Chamber of Commerce, 2012
• Coauthor. "The Changing Law of Multiparty Patent Infringement in the U.S. and How It Differs from Europe: Part Two," Bloomberg Law Reports, Sept. 19, 2011.
• Coauthor. "The Changing Law of Multiparty Patent Infringement in the U.S. and How It Differs from Europe: Part One," Bloomberg Law Reports, Sept. 12, 2011.
• Coauthor. "The Myriad Scare: Isolated DNA Molecules Remain Patent Eligible (for now!)," CIPA Journal, Sept. 2011.
• Coauthor. "What's Next for the U.S.—The Metric System?: A Quick Look at the "Imminent" Major U.S. Patent Law Reform" CIPA Journal, June 2011.
• Coauthor. "USPTO First Action Interview Pilot Program Redux," CIPA Journal, Sept. 2010 (Republished in Intellectual Property Magazine, Sept. 2010).
• Coauthor. "USPTO Backlog Impacts Biopharma Industry," Genetic Engineering & Biotechnology News, Sept. 1, 2008.
• Coauthor. "The USPTO Strikes Back: Proposed Fundamental Changes to the U.S. Patent System," Journal of Intellectual Property Law & Practice, May 2007.
• Coauthor. "The Effect of the U.S. Supreme Court’s Decision in eBay v. MercExchange on the Biopharmaceutical Industry," BNA International’s IP & Technology Programme, June 2006.